

China Botanic hires Zhao to gain NYSE compliance

25 January 2013 | News | By BioSpectrum Bureau



Singapore: China Botanic Pharmaceutical has appointed Mr Jack Zhao as a member of the company's board of directors. Mr Zhao will serve as an independent director, chairman of the board's audit committee, the audit committee financial expert, and as a member of the company's compensation and the nomination committees.

Mr Zhao, 31, has served as the cash management manager at Dreyfus Commodities (BJ) Trading since May 2012. Before that, he was employed as a finance manager with Glencore China and as a transactional banking manager with Standard Chartered Bank, China. Mr Zhao has also held the Chartered Financial Analyst (CFA) charter holder designation since September 2011.

He graduated with a master's degree in finance from the University of International Business and Economics, Beijing, in 2006 and he received a bachelor's degree in economic information management from the same university in 2004.

"We look forward to working with Mr Zhao to further improve our financial management and internal controls while implementing best practices as a public company. In addition, we believe that Mr Zhao's joining the board will enable us to regain compliance with Section 803(B)(2)(a)(iii) of the NYSE MKT company guide, which requires that at least one member of the audit committee be financially sophisticated," commented Mr Shaoming Li, chairman and CEO, China Botanic.